Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive degenerative lung disease leading to respiratory failure and death. Although anti-fibrotic drugs are now available for treating IPF, their clinical efficacy is limited and lung transplantation remains the only modality to prolong survival...
Main Authors: | Francesca Ruscitti, Francesca Ravanetti, Valeria Bertani, Luisa Ragionieri, Laura Mecozzi, Nicola Sverzellati, Mario Silva, Livia Ruffini, Valentina Menozzi, Maurizio Civelli, Gino Villetti, Franco Fabio Stellari |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01117/full |
Similar Items
-
Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01) -
Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice
by: Francesca Ruscitti, et al.
Published: (2017-04-01) -
Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis
by: Gali Epstein Shochet, et al.
Published: (2021-03-01) -
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
by: Michael Kreuter, et al.
Published: (2019-04-01) -
South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)